Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eye Disorders Are Focus Of Novel Neurostimulation Technologies

Executive Summary

Neurostimulation technology is migrating into the ophthalmology field, and the implications could be significant for the millions of patients worldwide with degenerative eye diseases, including retinitis pigmentosa and age-related macular degeneration, as well as those with moderate-to-severe dry eye disease. Companies active in this space include Second Sight Medical Products, Retina Implant AG, Pixium Vision, Nano Retina, and many others.

Advertisement

Related Content

CMS Proposes To Deny Most HCPCS Code Requests For DMEPOS Items
Six Devices, Diagnostics Among Cleveland Clinic’s Top 10 Innovations For 2014
Medicare Bonus Payments Awarded To Cook’s Stent, Second Sight’s Eye Implant
Emerging Peripheral Nerve Technologies Draw New Competitors To Neuromodulation Market
Neuromodulation Market: Innovation Brings High-Growth Rewards

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT035735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel